Moss Genomics closes $100,000 private placement

Mr. Jack Liu reports MOSS GENOMICS ANNOUNCES CLOSING OF FINANCING ROUND Effective as of Nov. 11, 2025, Moss Genomics Inc. has closed a non-brokered private placement of 555,555 common shares at 18 cents per share for gross proceeds of $100,000. No finders' fees were paid. Net proceeds will be used for general working capital. In addition, effective as of Nov. 11, 2025, Moss issued an aggregate 5,164,213 common shares at a deemed price of 18 cents per share as consideration under asset purchase agreements entered into between May 13, 2025, and July 14, 2025, pursuant to which the company acquired approximately 224.7523 ethereum at an average price of $3,833 per ETH (aggregate deemed consideration $966,435). This announcement represents the official completion of the private placement and related share issuances first announced on Feb. 3, 2025. Following completion of the foregoing transactions, Moss has 63,414,545 common shares issued and outstanding. All securities issued are subject to applicable statutory hold periods under Canadian securities laws. Annual and special general meeting scheduled for Nov. 13, 2025 Moss will hold its annual and special general meeting on Nov. 13, 2025, to be conducted virtually. Meeting time, access instructions, record date and matters of business will be set out in the company's meeting materials and have been posted on its website. About Moss Genomics Inc. Moss Genomics is developing a secure and user-controlled platform for genomic data, enabling individuals to vault their DNA, manage access permissions and participate in research monetization opportunities. Moss is building on ethereum-based infrastructure, with ETH used to finance development, DNA sequencing services and future platform operations. The company's mission is to advance decentralized and privacy-preserving genomics through real-world applications in health, identity and research. We seek Safe Harbor.